ATYR vs OBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ATYR Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to aTyr Pharma, Inc. Common Stock (ATYR) driven by superior Growth & Margin, Momentum & Technical while OBIO counters with relative strength in Options & Structure. Fundamentally, ATYR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus OBIO at N/M Forward P/E and -195.4% operating margin (-89.4% YoY). In options structure, ATYR sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro) against OBIO sits in BREAKOUT (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ATYR Revenue | OBIO Revenue | ATYR Op. Margin | OBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -5445.0% | N/A | ATYR |
| FY2020 | $10M | N/A | -152.2% | N/A | ATYR |
| FY2022 | $10M | $0M | -446.8% | -924.3% | ATYR |
| FY2023 | $0M | $0M | -15557.8% | -1866.2% | OBIO |
| FY2024 | $0M | $0M | -28899.6% | -2437.5% | OBIO |
| FY2025 | $0M | $30M | -40856.3% | -154.7% | OBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ATYR | OBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.6M | $570.6M | Larger Scale | OBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -89.4% | Higher Growth | ATYR |
| Operating Margin (TTM) Profitability | 0.0% | -195.4% | Higher Margin | ATYR |
| Net Profit Margin Profitability | 0.0% | -182.5% | Higher Margin | ATYR |
| Return on Equity (ROE) Capital Efficiency | -93.7% | -182.3% | Higher ROE | ATYR |
| 52-Week Range Position Momentum | 62% ($0โ$8) | 90% ($3โ$7) | Stronger Trend | OBIO |
| Beta / 30D Volatility Risk Regime | -9.67ฮฒ ยท 13806% Vol | 1.15ฮฒ ยท 80% Vol | Lower Realized Risk | OBIO |
| Unified Institutional Score Composite Signal | 34.3 / 100 (SELL) | 42.9 / 100 (HOLD) | Higher Composite | OBIO |